Leo Cancer Care Raises $40 Mn in Funding to Boost Radiation Therapy System

The company develops upright radiation therapy solutions, including a real-time, image-guided proton treatment system that eliminates the need for a gantry

Leo Cancer Care, a leading company for radiotherapy solutions, has raised $40 Mn in funding led by Catalio Capital Management.

This investment aims to boost the commercialization of Leo Care’s next-generation upright radiotherapy system, designed to enhance patient outcomes and broaden access to advanced cancer treatment.

Stephen Towe, Co-Founder and CEO of Leo Cancer Care, said, "We are very excited to welcome Catalio as an investor. The trust and support of new and returning investors highlight the growing recognition of upright radiotherapy's potential to improve patient experiences and expand access to advanced treatments globally."

About Leo Cancer Care

The company develops upright radiation therapy solutions, including a real-time, image-guided proton treatment system that eliminates the need for a gantry. Instead, it uses a fixed radiation beam combined with slow patient rotation in a seated or perched position.

The company also offers an upright particle therapy system with gradual patient rotation, enabling the use of smaller treatment rooms and more efficient therapy delivery.

Dr. Nicholas von Guionneau from Catalio Capital Management, who had Leo Cancer Care's board as an Observer as part of funding, said, "Leo Cancer Care has developed a new technology platform focused on upright patient positioning, unlocking a pipeline of pioneering therapeutic and diagnostic products with immense potential to improve patient care. Catalio is proud to support Leo's mission through its proton therapy expansion and the upcoming launch of photon therapy."

Earlier, one of Leo Cancer Care's flagship products, Marie, an upright patient positioning system and CT scanner for proton therapy that replaces traditional gantry rotation with patient rotation designed to reduce the size, cost, and complexity of proton therapy, has received 510(k) clearance from the U.S. Food and Drug Administration (FDA), and reportedly several leading cancer centers in the U.S. have already installed the technology.

Also, reports suggest that, later this month, Leo Cancer Care plans to unveil a new photon therapy product specifically designed for upright patient treatments.

Stay tuned for more such updates on Digital Health News